On September 23, 2026 ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies, reported the appointment of Peter Olagunju as Chief Executive Officer. Olagunju joins ImmunoScape as the company prepares to advance its Seed and Boost platform into the clinic. Co-founder Michael Fehlings, Ph.D., continues to lead the company’s scientific and technical strategy as Chief Technology Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Peter is the rare executive who has done this at every stage: building manufacturing platforms from academic starting points, guiding products through regulatory approval, and running a company from formation through successful outcomes. He has helped bring seven therapies to commercialization and knows how to build lean, capital-efficient organizations," said Adrian Bot, MD, Ph.D., ImmunoScape Board Member and former Chief Scientific Officer of both Kite Pharma and Capstan Therapeutics. "As ImmunoScape moves from platform to clinic, that combination of technical depth and operating judgment is precisely what the company needs."

Olagunju brings more than 20 years of experience in clinical development, manufacturing, and technical operations, and has contributed to seven approved products, including PROVENGE, ZYNTEGLO, ABECMA, ADSTILADRIN, SKYSONA, and LYFGENIA. He most recently served as Chief Executive Officer of a Catalio Capital-backed oncology company, which he led from formation through a $14 million seed financing to a successful corporate transaction.

He previously held Chief Operating Officer and Chief Technology Officer roles at TCR² Therapeutics, where he served as the operations lead on the company’s acquisition by Adaptimmune, and has held senior executive positions at FerGene and bluebird bio. Olagunju is Chairman of the Board of March Biosciences and holds an M.B.A. from the University of Washington’s Foster School of Business and a B.S. in Biology from the University of Illinois at Urbana-Champaign.

"Solid tumors have been the hardest problem in cell therapy, and the limiting factor has consistently been persistence — getting engineered T cells to survive and keep working inside the tumor," said Olagunju. "ImmunoScape’s Seed-and-Boost approach goes directly at that problem, and it does so with a platform that applies across autologous, allogeneic, and in vivo delivery. I’ve spent my career translating academic science into manufacturing and clinical execution at scale, and that is exactly what this moment calls for. My immediate priority is working with our partners to move our platform into the clinic."

(Press release, immunoSCAPE, SEP 23, 2026, View Source [SID1234671026])

On September 23, 2026 Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), reported its financial results for the first half year 2026 ended June 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First Half 2026 financial review

As of June 30, 2026, the Company’s cash position amounted to €0.1 million.

Noteworthy is the event post balance sheet date (June 30), namely the capital increase with €0.5 million dated July 16, 2026 which has strengthened the cash position.

After due consideration of detailed budgets and estimated cash flow forecasts for the years 2026 and 2027, the Company projects that its existing cash and cash equivalents will be sufficient to fund its estimated operating and capital expenditures into 2027.

Key financial figures for first half 2026, compared with the first half of 2025 and full year 2025, are summarized below:

Selected key financial figures (€ millions) Half Year Half Year Full Year
30-Jun-26 30-Jun-25 31-Dec-25
Revenue – (0,01) 0,02
Employee benefit expense (0,4) (1,4) (3,6)
Other operating expenses (1,0) (2,5) (4,6)
Other income 0,3 0,2 8,3
Operating profit/(loss) (1,2) (3,7) 0,9
Profit/(loss) for the period/year (1,2) (3,7) 0,8
Net cash used in operations (1,5) (3,3) (6,9)
Cash and cash equivalents 0,1 0,8 1,7
The Company’s license and collaboration agreements generated no revenue in the first half of 2026, which is similar to the first half of 2025.

The total employee benefit expenses decreased significantly to €0,4 million for the six-month period ended June 30, 2026, compared to €1,4 million in the same period of 2025. The decrease is primarily attributable to the workforce reduction implemented during 2025.

Other operating expenses amounted to €0,9 million at June 30, 2026, and decreased €1,6 million compared with the same period in 2025. Overall, the reduction in other operating expenses during the first half of 2026 reflects lower external service costs, a decline in research and development spending, and continued cost control across several operational expenditure categories. The decrease is also attributable to the Company’s strategic divestments, notably the disposal of the R&D facility in 2025 and the catheter business in 2026, which resulted in a lower operating cost base and reduced spending requirements compared to the prior-year period.

For the six-month period ended June 30, 2026, other income is mainly related to a marginal gain on the sale of the C-Cath business.

Net loss was €1,2 million, or € (0,027) per share, for the first half of 2026 compared to a net loss of €3,7 million, or € (0,09) per share, for the same period of 2025.

Net cash used in operations was €1,5 million for the first half of 2026 compared to €3,3 million for the first half of 2025.

The interim financial report for first half 2026 of the Company can be found on our website: View Source

(Press release, Celyad, SEP 23, 2026, View Source [SID1234671024])

On September 23, 2026 Allotera Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, reported the opening of the minimal residual disease (MRD)-positive cohort of its global pivotal T-RRex study of Soficabtagene Geleucel (Sofi-cel).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Opening the MRD-positive cohort allows us to reach patients earlier in their disease course, before relapse, when we believe Sofi-cel may have the potential to provide meaningful clinical benefit," said Kumar Srinivasan, Ph.D., M.B.A., President and Chief Executive Officer of Allotera. "This expansion of our T-RRex study demonstrates our commitment to exploring the potential of Sofi-cel across the treatment continuum for patients with T-ALL or T-LBL."

"MRD positivity after standard therapy is one of the strongest predictors of relapse, yet few therapies are directed specifically at eliminating residual disease," said Cherry Thomas, M.D., Chief Medical Officer of Allotera. "By evaluating Sofi-cel in patients with MRD positivity, we aim to determine whether treatment can achieve MRD-negative remission and ultimately improve long-term clinical outcomes."

T-RRex is a global, single-arm, open-label Phase 2 study with a pivotal cohort evaluating Sofi-cel in patients with R/R T-ALL/T-LBL. The study is also evaluating Sofi-cel in patients who are in remission and remain MRD-positive following standard therapy. The study is being conducted at 18 clinical sites in the U.S. and Australia.

About Soficabtagene Geleucel (Sofi-cel)

Sofi-cel is an allogeneic, off-the-shelf, CD7-targeted CAR-T cell therapy being developed for T-cell cancers. Allotera uses CRISPR/Cas9 gene editing to delete CD7 and the T-cell receptor alpha constant (TRAC) genes, an approach intended to prevent CAR-T cell fratricide and mitigate the risk of graft-versus-host disease.

Sofi-cel is manufactured in the United States using healthy donor-derived T cells, which is intended to avoid malignant cell contamination that can occur in the autologous CAR-T setting. Sofi-cel is currently being evaluated in a global pivotal clinical trial for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma and patients who are in remission but remain MRD-positive following standard therapy. More information on the pivotal trial is available at ClinicalTrials.gov, identifier NCT06514794.

Sofi-cel has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration for the treatment of relapsed or refractory T-ALL/T-LBL, as well as Priority Medicines, or PRIME, designation in the European Union. RMAT and PRIME designations provide increased agency support to expedite the development and review of promising therapies for patients with medical need. Sofi-cel was also selected to participate in the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program.

(Press release, Allotera Therapeutics, SEP 23, 2026, View Source [SID1234671022])

On September 23, 2026 Cartherics reported at two leading cell therapy conferences in Boston, sharing insights into the development and manufacture of scalable, off-the-shelf CAR-NK therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the 6th Annual iPSC Summit, Cartherics’ Head of Clinical Manufacturing, Dr Damien Zanker, presented ‘Manufacturing iPSC Therapies at Scale: Advancing Off-the-Shelf CAR-NK Production’ on 10 September.

The presentation highlighted Cartherics’ approach to building a scalable, consistent and secure iPSC manufacturing platform designed to support reliable CAR-iNK production. By engineering cells at the iPSC stage and establishing fully-characterised master cell banks, we create the starting point for a well-controlled differentiation process, providing the basis for enhanced product consistency and scalability – key attributes for developing off-the-shelf cell therapies.

Dr Zanker also presented at the 11th Annual CAR-TCR Summit on 17 September, with a presentation titled ‘Building Quality into iPSCs Early to Minimize Testing, Improve Reproducibility & Accelerate Commercialization.’

The presentation discussed how genetic engineering and quality considerations can be incorporated early in iPSC development to reduce downstream testing, improve reproducibility and support more efficient manufacturing.

Together, the presentations highlighted the important role of manufacturing in advancing iPSC-based cell therapies from research and development towards clinical application.

Cartherics is applying this manufacturing-led approach to its pipeline, including CTH-401, an iPSC-derived TAG-72 CAR-iNK therapy for relapsed/refractory ovarian cancer, which is progressing through IND-enabling activities ahead of first-in-human studies.

Cartherics was pleased to contribute its experience and perspective to discussions with the global iPSC and cell therapy communities in Boston.

(Press release, Cartherics, SEP 23, 2026, View Source [SID1234671021])

On September 23, 2026 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, reported that topline results from the Combi-TED Phase 2 international clinical trial of Tedopi in metastatic Non-Small Cell Lung Cancer sponsored by FoRT have been selected for an oral presentation at the 2026 Annual Meeting of the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) in Madrid, Spain (October 23-27, 2026).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Federico Cappuzzo, MD, PhD, Director of Medical Oncology at the National Cancer Institute Regina Elena (Rome, Italy) and Lead Investigator of the trial, will present topline results from the Combi-TED trial evaluating Tedopi in second-line treatment in combination with anti-PD1 or chemotherapy in patients with metastatic Non-Small Cell Lung Cancer (NSCLC).

"Results of a multicenter, phase II, open-label, randomized trial evaluating OSE2101 plus docetaxel or OSE2101 plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer (NSCLC) progressing after first-line chemo-immunotherapy"

Rapid Oral Presentation
Session: Non-Small Cell Lung Cancer, Metastatic
Abstract 2661RO
Room: Barcelona Auditorium, Hall 9
October 25, 2026, 8:30-10:00am CET
Combi-TED is an open label, randomized, three-arm Phase 2 study evaluating Tedopi in combination with the anti-PD1 immune checkpoint inhibitor Opdivo (nivolumab), with docetaxel or docetaxel alone (reference arm) as second-line treatment in 105 HLA-A2 positive patients with metastatic NSCLC and no evidence of EGFR mutations or ALK or ROS1 rearrangement, after first-line chemo-immunotherapy. The primary endpoint is 1-year survival rate. The trial is conducted in 23 sites in France, Italy and Spain.
(NCT04884282).

(Press release, OSE Immunotherapeutics, SEP 23, 2026, View Source [SID1234671012])